Expert Consensus on Dual Antiplatelet Therapy (DAPT)
for Acute Coronary Syndrome in Thailand: Review Article
Kunjara-Na-Ayudhya R, MD¹, Buddhari W, MD², Sookananchai B, MD³, Kuanprasert S, MD⁴,
Chamnarnphol N, MD⁵, Sukonthasarn A, MD⁴
Affiliation : ¹ Heart Center, Vichaiyut Hospital, Bangkok, Thailand ² Division of Cardiovascular Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand ³ Department of Medicine, Maharat Nakhon Ratchasima Hospital, Nakhon Ratchasima, Thailand ⁴ Cardiology Division, Department of Internal Medicine, Faculty of Medicine, Chiang Mai University, Thailand ⁵ Division of Cardiology, Department of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand
Acute coronary syndrome (ACS) is an emergency condition that may lead to severe morbidity or mortality. One factor that may
improve mortality in ACS is dual antiplatelet therapy (DAPT) with a P2Y₁₂ receptor blocker on top of aspirin. Recently, several
guidelines recommended DAPT in ACS patients. This consensus aimed to summarize how to choose the appropriate DAPT for
ACS patients based on guidelines and clinical trials to ensure the best patient outcomes. The recommendations of DAPT for
the eight settings of ACS, which are STEMI with primary percutaneous coronary intervention (PCI), ST elevation myocardial
infarction (STEMI) with fibrinolytics, STEMI without reperfusion therapy, non-ST elevation acute coronary syndrome (NSTE-
ACS) with PCI, medically managed NSTE-ACS, maintenance DAPT in ACS, recurrent ACS, and ACS in the elderly, are reported.
Keywords : Acute coronary syndrome, Dual antiplatelet therapy, P2Y₁₂ receptor blocker, ST elevation myocardial infarction,
Non-ST elevation acute coronary syndrome
All Articles
Download